410 related articles for article (PubMed ID: 28483786)
1. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
2. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
Lane WS; Favaro E; Rathor N; Jang HC; Kjærsgaard MIS; Oviedo A; Rose L; Senior P; Sesti G; Soto Gonzalez A; Franek E
Diabetes Care; 2020 Aug; 43(8):1710-1716. PubMed ID: 32209647
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
[TBL] [Abstract][Full Text] [Related]
5. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
[TBL] [Abstract][Full Text] [Related]
6. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
[TBL] [Abstract][Full Text] [Related]
8. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
9. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
10. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
[TBL] [Abstract][Full Text] [Related]
11. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial.
Komatsu M; Ekelund M; Horio H; Kadowaki T
Endocr J; 2021 Apr; 68(4):429-440. PubMed ID: 33390422
[TBL] [Abstract][Full Text] [Related]
13. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.
Blevins T; Zhang Q; Frias JP; Jinnouchi H; Chang AM;
Diabetes Care; 2020 Dec; 43(12):2991-2998. PubMed ID: 32616612
[TBL] [Abstract][Full Text] [Related]
14. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
[TBL] [Abstract][Full Text] [Related]
15. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan.
Kawamura T; Kikuchi T; Horio H; Rathor N; Ekelund M
Endocr J; 2021 Apr; 68(4):409-420. PubMed ID: 33518615
[TBL] [Abstract][Full Text] [Related]
17. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Kellerer M; Kaltoft MS; Lawson J; Nielsen LL; Strojek K; Tabak Ö; Jacob S
Diabetes Obes Metab; 2022 Sep; 24(9):1788-1799. PubMed ID: 35546450
[TBL] [Abstract][Full Text] [Related]
18. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
Rodbard HW; Tripathy D; Vidrio Velázquez M; Demissie M; Tamer SC; Piletič M
Diabetes Obes Metab; 2017 Oct; 19(10):1389-1396. PubMed ID: 28345792
[TBL] [Abstract][Full Text] [Related]
19. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
Senior P; Hramiak I
Can J Diabetes; 2019 Oct; 43(7):515-523. PubMed ID: 30872107
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]